Yibao Zhang

Personalized Assessment of kV Cone Beam Computed Tomography Doses in Image-guided Radiotherapy of Pediatric Cancer Patients

PURPOSE To develop a quantitative method for the estimation of kV cone beam computed tomography (kVCBCT) doses in pediatric patients undergoing image-guided radiotherapy. METHODS AND MATERIALS Forty-two children were retrospectively analyzed in subgroups of different scanned regions: one group in the head-and-neck and the other group in the pelvis. Critical structures in planning CT images were delineated on an Eclipse treatment planning system before being converted into CT phantoms for Monte Carlo simulations. A benchmarked EGS4 Monte Carlo code was used to calculate three-dimensional dose distributions of kVCBCT scans with full-fan high-quality head or half-fan pelvis protocols predefined by the manufacturer. Based on planning CT images and structures exported in DICOM RT format, occipital-frontal circumferences (OFC) were calculated for head-and-neck patients using DICOMan software. Similarly, hip circumferences (HIP) were acquired for the pelvic group. Correlations between mean organ doses and age, weight, OFC, and HIP values were analyzed with SigmaPlot software suite, where regression performances were analyzed with relative dose differences (RDD) and coefficients of determination (R(2)). RESULTS kVCBCT-contributed mean doses to all critical structures decreased monotonically with studied parameters, with a steeper decrease in the pelvis than in the head. Empirical functions have been developed for a dose estimation of the major organs at risk in the head and pelvis, respectively. If evaluated with physical parameters other than age, a mean RDD of up to 7.9% was observed for all the structures in our population of 42 patients. CONCLUSIONS kVCBCT doses are highly correlated with patient size. According to this study, weight can be used as a primary index for dose assessment in both head and pelvis scans, while OFC and HIP may serve as secondary indices for dose estimation in corresponding regions. With the proposed empirical functions, it is possible to perform an individualized quantitative dose assessment of kVCBCT scans.

A dosimetric evaluation of knowledge-based VMAT planning with simultaneous integrated boosting for rectal cancer patients.

RapidPlan, a commercial knowledge‐based optimizer, has been tested on head and neck, lung, esophageal, breast, liver, and prostate cancer patients. To appraise its performance on VMAT planning with simultaneous integrated boosting (SIB) for rectal cancer, this study configured a DVH (dose‐volume histogram) estimation model consisting 80 best‐effort manual cases of this type. Using the model‐ generated objectives, the MLC (multileaf collimator) sequences of other 70 clinically approved plans were reoptimized, while the remaining parameters, such as field geometry and photon energy, were maintained. Dosimetric outcomes were assessed by comparing homogeneity index (HI), conformal index (CI), hot spots (volumes receiving over 107% of the prescribed dose, V107%), mean dose and dose to the 50% volume of femoral head (Dmean_FH and D50%_FH), and urinary bladder (Dmean_UB and D50%_UB), and the mean DVH plotting. Paired samples t‐test or Wilcoxon signed‐rank test suggested that comparable CI were achieved by RapidPlan (0.99 ± 0.04 for PTVboost, and 1.03 ± 0.02 for PTV) and original plans (1.00 ± 0.05 for PTVboost and 1.03 ± 0.02 for PTV), respectively (p > 0.05). Slightly improved HI of planning target volume (PTVboost) and PTV were observed in the RapidPlan cases (0.05 ± 0.01 for PTVboost, and 0.26 ± 0.01 for PTV) than the original plans (0.06 ± 0.01 for PTVboost and 0.26 ± 0.01 for PTV), p < 0.05. More cases with positive V107% were found in the original (18 plans) than the RapidPlan group (none). RapidPlan significantly reduced the D50%_FH (by 1.53 Gy/9.86% from 15.52 ± 2.17 to 13.99 ± 1.16 Gy), Dmean_FH (by 1.29 Gy/7.78% from 16.59±2.07 to 15.30±0.70 G), D50%_UB (by 4.93 Gy/17.50% from 28.17±3.07 to 23.24±2.13 Gy), and Dmean_UB (by 3.94 Gy/13.43% from 29.34±2.34 to 25.40±1.36 Gy), respectively. The more concentrated distribution of RapidPlan data points indicated an enhanced consistency of plan quality. PACS number(s): 87.55.de; 87.55.dkRapidPlan, a commercial knowledge-based optimizer, has been tested on head and neck, lung, esophageal, breast, liver, and prostate cancer patients. To appraise its performance on VMAT planning with simultaneous integrated boosting (SIB) for rectal cancer, this study configured a DVH (dose-volume histogram) estimation model consisting 80 best-effort manual cases of this type. Using the model- generated objectives, the MLC (multileaf collimator) sequences of other 70 clinically approved plans were reoptimized, while the remaining parameters, such as field geometry and photon energy, were maintained. Dosimetric outcomes were assessed by comparing homogeneity index (HI), conformal index (CI), hot spots (volumes receiving over 107% of the prescribed dose, V107%), mean dose and dose to the 50% volume of femoral head (Dmean_FH and D50%_FH), and urinary bladder (Dmean_UB and D50%_UB), and the mean DVH plotting. Paired samples t-test or Wilcoxon signed-rank test suggested that comparable CI were achieved by RapidPlan (0.99 ± 0.04 for PTVboost, and 1.03 ± 0.02 for PTV) and original plans (1.00 ± 0.05 for PTVboost and 1.03 ± 0.02 for PTV), respectively (p > 0.05). Slightly improved HI of planning target volume (PTVboost) and PTV were observed in the RapidPlan cases (0.05 ± 0.01 for PTVboost, and 0.26 ± 0.01 for PTV) than the original plans (0.06 ± 0.01 for PTVboost and 0.26 ± 0.01 for PTV), p < 0.05. More cases with positive V107% were found in the original (18 plans) than the RapidPlan group (none). RapidPlan significantly reduced the D50%_FH (by 1.53 Gy/9.86% from 15.52 ± 2.17 to 13.99 ± 1.16 Gy), Dmean_FH (by 1.29 Gy/7.78% from 16.59±2.07 to 15.30±0.70 G), D50%_UB (by 4.93 Gy/17.50% from 28.17±3.07 to 23.24±2.13 Gy), and Dmean_UB (by 3.94 Gy/13.43% from 29.34±2.34 to 25.40±1.36 Gy), respectively. The more concentrated distribution of RapidPlan data points indicated an enhanced consistency of plan quality. PACS number(s): 87.55.de; 87.55.dk.

Photon Optimizer (PO) prevails over Progressive Resolution Optimizer (PRO) for VMAT planning with or without knowledge‐based solution

&NA; The enhanced dosimetric performance of knowledge‐based volumetric modulated arc therapy (VMAT) planning might be jointly contributed by the patient‐specific optimization objectives, as estimated by the RapidPlan model, and by the potentially improved Photon Optimizer (PO) algorithm than the previous Progressive Resolution Optimizer (PRO) engine. As PO is mandatory for RapidPlan estimation but optional for conventional manual planning, appreciating the two optimizers may provide practical guidelines for the algorithm selection because knowledge‐based planning may not replace the current method completely in a short run. Using a previously validated dose‐volume histogram (DVH) estimation model which can produce clinically acceptable plans automatically for rectal cancer patients without interactive manual adjustment, this study reoptimized 30 historically approved plans (referred as clinical plans that were created manually with PRO) with RapidPlan solution (PO plans). Then the PRO algorithm was utilized to optimize the plans again using the same dose‐volume constraints as PO plans, where the line objectives were converted as a series of point objectives automatically (PRO plans). On the basis of comparable target dose coverage, the combined applications of new objectives and PO algorithm have significantly reduced the organs‐at‐risk (OAR) exposure by 23.49–32.72% than the clinical plans. These discrepancies have been largely preserved after substituting PRO for PO, indicating the dosimetric improvements were mostly attributable to the refined objectives. Therefore, Eclipse users of earlier versions may instantly benefit from adopting the model‐generated objectives from other RapidPlan‐equipped centers, even with PRO algorithm. However, the additional contribution made by the PO relative to PRO accounted for 1.54–3.74%, suggesting PO should be selected with priority whenever available, with or without RapidPlan solution as a purchasable package. Significantly increased monitor units were associated with the model‐generated objectives but independent from the optimizers, indicating higher modulation in these plans. As a summary, PO prevails over PRO algorithm for VMAT planning with or without knowledge‐based technique.

CT scans in childhood and risk of leukaemia and brain tumours

www.thelancet.com Vol 380 November 17, 2012 1735 Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/ between 1 and 5 years. Therefore brain doses in these ages should be diff erent. To design retrospective studies with 23 years of follow-up in the imaging specialty is a true challenge because improvements in technology and especially in dose reduction will have been tremendous over that period. Nevertheless, we agree with Pearce and colleagues that MRI devices, the diagnostic performances of which now compete with those of CT in many diseases, should be encouraged.

A comparative study of identical VMAT plans with and without jaw tracking technique

The unwanted radiation transmission through the multileaf collimators could be reduced by the jaw tracking technique which is commercially available on Varian TrueBeam accelerators. On the basis of identical plans, this study aims to investigate the dosimetric impact of jaw tracking on the volumetric‐modulated arc therapy (VMAT) plans. Using Eclipse treatment planning system (TPS), 40 jaw‐tracking VMAT plans with various tumor volumes and shapes were optimized. Fixed jaw plans were created by editing the jaw coordinates of the jaw‐tracking plans while other parameters were identical. The deliverability of this artificial modification was verified using COMPASS system via three‐dimentional gamma analysis between the measurement‐based reconstruction and the TPS‐calculated dose distribution. Dosimetric parameters of dose‐volume histogram (DVH) were compared to assess the improvement of dose sparing for organs at risk (OARs) in jaw‐tracking plans. COMPASS measurements demonstrated that over 96.9% of structure volumes achieved gamma values less than 1.00 at criteria of 3 mm/3%. The reduction magnitudes of maximum and mean dose to various OARs ranged between 0.06%∼6.76%(0.04∼7.29 Gy) and 0.09%∼7.81%(0.02∼2.78 Gy), respectively, using jaw tracking, agreeing with the disparities of radiological characteristics between MLC and jaws. Jaw tracking does not change the delivery efficiency and total monitor units. The dosimetric comparison of VMAT plans with and without jaw tracking confirms the physics hypotheses that reduced transmission through tracking jaws will reduce doses to OARs without sacrificing the target dose coverage because it is meant to be covered by radiation beams going through the opening. PACS number(s): 87.55.de, 87.55.dkThe unwanted radiation transmission through the multileaf collimators could be reduced by the jaw tracking technique which is commercially available on Varian TrueBeam accelerators. On the basis of identical plans, this study aims to investigate the dosimetric impact of jaw tracking on the volumetric-modulated arc therapy (VMAT) plans. Using Eclipse treatment planning system (TPS), 40 jaw-tracking VMAT plans with various tumor volumes and shapes were optimized. Fixed jaw plans were created by editing the jaw coordinates of the jaw-tracking plans while other parameters were identical. The deliverability of this artificial modification was verified using COMPASS system via three-dimentional gamma analysis between the measurement-based reconstruction and the TPS-calculated dose distribution. Dosimetric parameters of dose-volume histogram (DVH) were compared to assess the improvement of dose sparing for organs at risk (OARs) in jaw-tracking plans. COMPASS measurements demonstrated that over 96.9% of structure volumes achieved gamma values less than 1.00 at criteria of 3 mm/3%. The reduction magnitudes of maximum and mean dose to various OARs ranged between 0.06%∼6.76%(0.04∼7.29 Gy) and 0.09%∼7.81%(0.02∼2.78 Gy), respectively, using jaw tracking, agreeing with the disparities of radiological characteristics between MLC and jaws. Jaw tracking does not change the delivery efficiency and total monitor units. The dosimetric comparison of VMAT plans with and without jaw tracking confirms the physics hypotheses that reduced transmission through tracking jaws will reduce doses to OARs without sacrificing the target dose coverage because it is meant to be covered by radiation beams going through the opening. PACS number(s): 87.55.de, 87.55.dk.

Concomitant Imaging Dose and Cancer Risk in Image Guided Thoracic Radiation Therapy

PURPOSE Kilovoltage cone beam computed tomography (CT) (kVCBCT) imaging guidance improves the accuracy of radiation therapy but imposes an extra radiation dose to cancer patients. This study aimed to investigate concomitant imaging dose and associated cancer risk in image guided thoracic radiation therapy. METHODS AND MATERIALS The planning CT images and structure sets of 72 patients were converted to CT phantoms whose chest circumferences (Cchest) were calculated retrospectively. A low-dose thorax protocol on a Varian kVCBCT scanner was simulated by a validated Monte Carlo code. Computed doses to organs and cardiac substructures (for 5 selected patients of various dimensions) were regressed as empirical functions of Cchest, and associated cancer risk was calculated using the published models. The exposures to nonthoracic organs in children were also investigated. RESULTS The structural mean doses decreased monotonically with increasing Cchest. For all 72 patients, the median doses to the heart, spinal cord, breasts, lungs, and involved chest were 1.68, 1.33, 1.64, 1.62, and 1.58 cGy/scan, respectively. Nonthoracic organs in children received 0.6 to 2.8 cGy/scan if they were directly irradiated. The mean doses to the descending aorta (1.43 ± 0.68 cGy), left atrium (1.55 ± 0.75 cGy), left ventricle (1.68 ± 0.81 cGy), and right ventricle (1.85 ± 0.84 cGy) were significantly different (P<.05) from the heart mean dose (1.73 ± 0.82 cGy). The blade shielding alleviated the exposure to nonthoracic organs in children by an order of magnitude. CONCLUSIONS As functions of patient size, a series of models for personalized estimation of kVCBCT doses to thoracic organs and cardiac substructures have been proposed. Pediatric patients received much higher doses than did the adults, and some nonthoracic organs could be irradiated unexpectedly by the default scanning protocol. Increased cancer risks and disease adverse events in the thorax were strongly related to higher imaging doses and smaller chest dimensions.

SU-D-9A-07: Imaging Dose and Cancer Risk in Image-Guided Radiotherapy of Cancers

PURPOSE To systematically evaluate the imaging doses and cancer risks associated with various imaging procedures involving ionizing radiation during image-guided radiotherapy of an increasingly large number of cancer patients. METHODS 141 patients (52 brain cases, 47 thoracic cases, 42 abdominal cases, aged 3 to 91 years old) treated between October 2009 and March 2010 were included in this IRB-approved retrospective study. During the whole radiotherapy course, each patient underwent at least one type of imaging procedures, i.e., kV portal, MV portal and kVCBCT, besides CT simulations. Based on Monte Carlo modeling and particle transport in human anatomy of various dimensions, the correlations between the radiation doses to the various organs-at-risk (OARs) at the head, the thoracic and the abdominal regions and ones weight, circumference, scan mAs and kVp have been obtained and used to estimate the radiation dose from a specific imaging procedure. The radiation-induced excess relative risk (ERR) was then estimated with BEIR VII formulism based on ones gender, age and radiation dose. 1+ ERR was reported in this study as relative cancer risk. RESULTS For the whole cohort of 141 patients, the mean imaging doses from various imaging procedures were 8.3 cGy to the brain, 10.5 cGy to the lungs and 19.2 cGy to the red bone marrow, respectively. Accordingly, the cancer risks were 1.140, 1.369 and 2.671, respectively. In comparison, MV portal deposited largest doses to the lungs while kVCBCT delivered the highest doses to the red bone marrow. CONCLUSION The compiled imaging doses to a patient during his/her treatment course were patient-specific and site-dependent, varying from 1.2 to 263.5 cGy on average, which were clinically significant and should be included in the treatment planning and overall decision-making. Our results indicated the necessity of personalized imaging to maximize its clinical benefits while reducing the associated cancer risks. Sichuan University Scholarship.

Imaging Dose, Cancer Risk and Cost Analysis in Image-guided Radiotherapy of Cancers

The purpose of this retrospective study is to evaluate the cumulative imaging doses, the associated cancer risk and the cost related to the various radiological imaging procedures in image-guided radiotherapy of cancers. Correlations between patients’ size and Monte Carlo simulated organ doses were established and validated for various imaging procedures, and then used for patient-specific organ dose estimation of 4,832 cancer patients. The associated cancer risk was estimated with published models and the cost was calculated based on the standard billing codes. The average (range) cumulative imaging doses to the brain, lungs and red bone marrow were 38.0 (0.5–177.3), 18.8 (0.4–246.5), and 49.1 (0.4–274.4) cGy, respectively. The associated average (range) lifetime attributable risk of cancer incidence per 100,000 persons was 78 (0–2798), 271 (1–8948), and 510 (0–4487) for brain cancer, lung cancer and leukemia, respectively. The median (range) imaging cost was

An interactive plan and model evolution method for knowledge‐based pelvic VMAT planning

5256 (4268–15896) for the head scans,

Fully automated searching for the optimal VMAT jaw settings based on Eclipse Scripting Application Programming Interface (ESAPI) and RapidPlan knowledge‐based planning

5180 (4268–16274) for the thorax scans, and